Restatement of Previously Issued Consolidated Financial Statements (Tables)

12 Months Ended

Dec. 31, 2023

Restatement of Previously Issued Consolidated Financial Statements

Summary of effect of the restatement on each financial statement line item

The following tables summarize the effect of the restatement on each financial statement line item as of the dates, and for the periods, indicated (in thousands):

Consolidated Statement of Operations and Comprehensive loss for the period from July 22, 2023 to December 31, 2023 (Successor)	As Reported		Adjustment		As Restated
Acquired in-process research and development	$	—	$	348,000	$	348,000
Total operating costs and expenses		(29,558)		348,000		318,442
Income (loss) from operations		29,558		(348,000)		(318,442)
Income (loss) before taxes		24,046		(348,000)		(323,954)
Net income (loss) and comprehensive income (loss)		24,046		(348,000)		(323,954)
Basic and diluted net income (loss) per share	$	0.65	$	(9.37)	$	(8.72)
Consolidated Statement of Convertible Preferred Stock and Stockholders' Deficit for the period from July 22, 2023 to December 31, 2023 (Successor)	As Reported		Adjustment		As Restated
Accumulated deficit, balance as of July 22, 2023 (Successor)	$	(180,856)	$	348,000	$	167,144
Net income (loss)	$	24,046	$	(348,000)	$	(323,954)